title: Bivalirudin in the cardiac cath lab: streamlining the percutaneous coronary intervention experience.
abstract: The common reasons that physicians do not use bivalirudin include concerns about cost, ease and speed of administration and difficulties knowing when to pull sheaths in the recovery area. We suggest that the use of bivalirudin in percutaneous coronary intervention (PCI) can reduce overall cath lab costs, does not delay care in coronary intervention and can actually reduce overall recovery time compared to traditional heparin-based therapy.
authors.affiliation: Baylor University Medical Center, Dallas, Texas, USA.
authors.forename: Jeffrey M
authors.initials: JM
authors.lastname: Schussler
mesh_terms: D000925:Anticoagulants / Q000008:administration & dosage; D000991:Antithrombins / Q000191:economics / Q000627:therapeutic use*; D006328:Cardiac Catheterization; D003365:Costs and Cost Analysis; D006493:Heparin / Q000008:administration & dosage; D006629:Hirudins / Q000191:economics; D006801:Humans; D010446:Peptide Fragments / Q000191:economics / Q000627:therapeutic use*; D062645:Percutaneous Coronary Intervention; D011994:Recombinant Proteins / Q000191:economics / Q000627:therapeutic use
chemical_list: D000925:Anticoagulants; D000991:Antithrombins; D006629:Hirudins; D010446:Peptide Fragments; D011994:Recombinant Proteins; D006493:Heparin; C074619:bivalirudin